GSK has taken another significant step in fortifying its burgeoning oncology pipeline after completing the £4 billion acquisition of Massachusetts-based biopharma Tesaro.
The deal – originally announced back in December 2018 – grants GSK access to Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.
Zejula is currently approved in the US and Europe as a treatment for adult patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status.
Clinical trials to assess the use of Zejula in “all-comers” patient populations, as a monotherapy and in combinations, for the significantly larger opportunity of first line maintenance treatment of ovarian cancer are also underway.
These ongoing trials are evaluating the potential benefit of Zejula in patients who carry gBRCA mutations as well as the larger population of patients without gBRCA mutations whose tumours are HRD-positive and HRD-negative. Results from the first of these studies, PRIMA, are expected to be available in the second half of 2019.
Dr Hal Barron, Chief Scientific Officer and President of R&D at GSK, said: “Both GSK and TESARO are driven by a focus on patients and a deep desire to develop truly transformational medicines that can improve and extend their lives.
“The acquisition of Tesaro, which we have completed today, significantly strengthens our oncology pipeline and brings new scientific capabilities and expertise that will increase the pace and scale at which we can help patients living with cancer.”
Dr Mary Lynne Hedley, President and Chief Operating Officer of Tesaro, added: “This new partnership between Tesaro and GSK marks an important milestone in advancing our mission of developing transformative therapies for individuals living with cancer.
“Together with GSK, we can accelerate and further advance Tesaro’s development and commercialisation initiatives and, ultimately provide more time for more patients.”